Pre-Open Stock Movers 12/02: (CFVI) (OMER) (DWAC) Higher; (TANH) (KIRK) (LE) Lower (more...)

December 2, 2021 9:27 AM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

(Updated - December 2, 2021 9:28 AM EST)

Pre-Open Stock Movers:

Tantech Holdings Ltd (NASDAQ: TANH) 56% LOWER; announced the pricing of an underwritten public offering of common shares, with gross proceeds to the Company expected to be approximately $13.7 million, before deducting underwriting discounts and commissions and other estimated expenses payable by the Company.

CF Acquisition Corp. VI (Nasdaq: CFVI) 41% HIGHER; Rumble Inc., the neutral video platform, and CF Acquisition Corp. VI (Nasdaq: CFVI) ("CFVI"), a special purpose acquisition company sponsored by Cantor Fitzgerald, today announced that they have entered into a definitive business combination agreement. Former President Trump was mentioned as haveing a deal with Rumble in the filing.

Kirkland's, Inc. (Nasdaq: KIRK) 27.8% LOWER; Net sales decreased 2.0% to $143.6 million, with 3.1% fewer stores. Comparable sales decreased 0.7%, including an e-commerce increase of 7.3%.

Omeros Corporation (Nasdaq: OMER) 20.4% HIGHER; announced that it has entered into a definitive agreement for the sale of OMIDRIA to Rayner Surgical Group Limited. Expected to close on or before December 31, 2021, the transaction includes an upfront payment of $125 million with an additional $200 million in a commercial milestone payment. Omeros will also retain its accounts receivable balance at the closing, which was $34 million at the end of last quarter. Together with substantial royalties to be paid by Rayner to Omeros on net sales of OMIDRIA, the transaction is valued in excess of $1 billion.

Digital World Acquisition Corp (NASDAQ: DWAC) 20% HIGHER; Former President Trump's new social media venture is seeking to raise up to $1 billion by selling shares to hedge funds and family offices at a valuation of close to $3 billion, according to Reuters, citing people familiar with the matter.

Lands' End (NASDAQ: LE) 15.9% LOWER; reported Q3 EPS of $0.22, $0.01 better than the analyst estimate of $0.21. Revenue for the quarter came in at $375.8 million versus the consensus estimate of $397 million. Lands' End sees Q4 2021 EPS of $0.27-$0.36, versus the consensus of $0.64. Lands' End sees Q4 2021 revenue of $560-575 million, versus the consensus of $590.9 million.

Snowflake (NYSE: SNOW) 13.3% HIGHER; reported Q3 revenues $334.4 million versus the consensus estimate of $305.51 million. Product revenue of $312.5 million, representing 110% year-over-year growth. Sees Q4 product revenue of $345-$350 million (up 94-96%). Sees FY product revenue of $1.126-$1.131 billion (up 103-104%).

Humanigen, Inc. (Nasdaq: HGEN) 9% HIGHER; announced today The Lancet Respiratory Medicine (“Lancet”), an internationally trusted, peer-reviewed source of clinical, public health, and global health knowledge, published positive results from Humanigen’s LIVE-AIR Phase 3 randomized, controlled trial of lenzilumab in hospitalized COVID-19 patients, as well as an independent expert commentary. The Lancet paper concludes “LIVE-AIR showed that lenzilumab treatment of hospitalised patients with COVID-19 can improve the likelihood of survival without the need for mechanical ventilation, with a safety profile similar to that of placebo.”2

Vir Biotechnology, Inc. (Nasdaq: VIR) 8.6% HIGHER; GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations1 of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralizing activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.

Five Below (NASDAQ: FIVE) 8.4% HIGHER; reported Q3 EPS of $0.43, $0.14 better than the analyst estimate of $0.29. Revenue for the quarter came in at $607.6 million versus the consensus estimate of $563.68 million. Five Below sees Q4 2021 EPS of $2.36-$2.48, versus the consensus of $2.49. Five Below sees Q4 2021 revenue of $985-1005 million, versus the consensus of $1000 million.

Elastic N.V. (NYSE: ESTC) 7.4% LOWER; reported Q2 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $206 million versus the consensus estimate of $194.57 million. Elastic N.V. sees Q3 2022 EPS of ($0.24)-($0.20), versus the consensus of ($0.22). Elastic N.V. sees Q3 2022 revenue of $207-209 million, versus the consensus of $202.59 million. Elastic N.V. sees FY2022 EPS of ($0.61)-($0.51), versus the consensus of ($0.60). Elastic N.V. sees FY2022 revenue of $826-832 million, versus the consensus of $813.74 million.

Okta, Inc. (NASDAQ: OKTA) 7% HIGHER; reported Q3 EPS of ($0.07), $0.16 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $351 million versus the consensus estimate of $327.01 million. Okta, Inc. sees Q4 2022 EPS of ($0.25)-($0.24), versus the consensus of ($0.28). Okta, Inc. sees Q4 2022 revenue of $358-360 million, versus the consensus of $354.8 million.

Veeva Systems (NYSE: VEEV) 5.6% LOWER; reported Q3 EPS of $0.88, in-line with the analyst estimate of $0.88. Revenue for the quarter came in at $479.1 million versus the consensus estimate of $465.91 million. Veeva Systems sees Q4 2022 EPS of $0.88, versus the consensus of $0.86. Veeva Systems sees Q4 2022 revenue of $478-480 million, versus the consensus of $479.5 million.

WeWork (NYSE: WE) 5.2% LOWER; Disclosed Non-Reliance on Previously Issued Financial Statements or Related Audit Report or Completed Interim Report.

Boeing (NYSE: BA) 4.6% HIGHER; China aviation authority issues airworthiness directive on Boeing 737 MAX.

Graco Inc. (NYSE: GGG) 3.5% HIGHER; William Blair upgraded from Market Perform to Outperform.

Apple (NASDAQ: AAPL) 3.3% LOWER; reportedly told suppliers that demand for the iPhone 13 lineup has weakened.

CrowdStrike Holdings Inc. (NASDAQ: CRWD) 3.2% HIGHER; reported Q3 EPS of $0.17, $0.07 better than the analyst estimate of $0.10. Revenue for the quarter came in at $380.1 million versus the consensus estimate of $363.48 million. CrowdStrike Holdings Inc. sees Q4 2022 EPS of $0.19-$0.21, versus the consensus of $0.16. CrowdStrike Holdings Inc. sees Q4 2022 revenue of $406.5-412.3 million, versus the consensus of $400 million.

C3.ai (NYSE: AI) 2.8% LOWER; reported Q2 EPS of ($0.23), $0.05 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $58.3 million versus the consensus estimate of $56.9 million. C3.ai sees Q3 2022 revenue of $66-68 million, versus the consensus of $65.6 million. Non-GAAP loss from operations ($26.0) - ($30.0). C3.ai sees FY2022 revenue of $248-251 million, versus the consensus of $246 million.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

William Blair, Cantor Fitzgerald, After-Hours Movers, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers, SPAC